Showing results (51-60 of 102) with videos related to
Sort By:
Pageof 11
Oncoimmunology|February 5, 2019
Batf3+ DCs and type I IFN are critical for the efficacy of neoadjuvant cancer immunotherapyJing Liu, Elisa A Rozeman, Jake S O'Donnell, et al.Nature Medicine|June 30, 2015
IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseasesMichele W L Teng, Edward P Bowman, Joshua J McElwee, et al.Cancer Research|February 22, 2014
Combined anti-CD40 and anti-IL-23 monoclonal antibody therapy effectively suppresses tumor growth and metastasesBianca von Scheidt, Patrick S K Leung, Michelle C R Yong, et al.Journal of Immunology (Baltimore, Md. : 1950)|April 20, 2010
Combination therapy of established tumors by antibodies targeting immune activating and suppressing moleculesKazuyoshi Takeda, Yuko Kojima, Tomoyasu Uno, et al.Cancer Research|September 17, 2016
Agonistic CD40 mAb-Driven IL12 Reverses Resistance to Anti-PD1 in a T-cell-Rich TumorShin Foong Ngiow, Arabella Young, Stephen J Blake, et al.Oncoimmunology|June 23, 2017
Selective activation of anti-CD73 mechanisms in control of primary tumors and metastasesDipti Vijayan, Deborah S Barkauskas, Kimberley Stannard, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 22, 2017
Co-administration of RANKL and CTLA4 Antibodies Enhances Lymphocyte-Mediated Antitumor Immunity in MiceElizabeth Ahern, Heidi Harjunpää, Deborah Barkauskas, et al.Cancer Immunology Research|June 21, 2018
Experimental Lung Metastases in Mice Are More Effectively Inhibited by Blockade of IL23R than IL23Juming Yan, Stacey Allen, Dipti Vijayan, et al.Cancer Research|October 7, 2010
Selective depletion of Foxp3+ regulatory T cells improves effective therapeutic vaccination against established melanomaKatjana Klages, Christian T Mayer, Katharina Lahl, et al.Cancer Research|April 17, 2008
Interleukin 21 enhances antibody-mediated tumor rejectionMark J Smyth, Michele W L Teng, Janelle Sharkey, et al.Pageof 11